The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a
Open accessAbstract
We examined the sera of six patients before and after i.v. infusions of autologous chronic lymphocytic leukemia (CLL) cells transduced ex vivo with an adenovirus encoding CD154 (Ad-CD154). Five patients made high-titer antibodies against adenovirus and three made IgG reactive with a leukemia-associated surface antigen, which we identified as ROR1. Anti-ROR1 antibodies were not detected in the sera of untreated patients. We generated anti-ROR1 mAbs and found they reacted specifically with the CLL cells of all patients, but not with nonleukemic leukocytes, a wide variety of normal adult tissues, or blood mononuclear cells, including CD5+B cells of healthy adults. ROR1 could bind Wnt5a, which induced activation of NF-κB when coexpressed with ROR1 in HEK293 cells and enhanced the survival of CLL cells in vitro, an effect that could be neutralized by posttreatment anti-ROR1 antisera. We conclude that patients with CLL can break immune tolerance to ROR1, which is an oncofetal surface antigen and survival-signaling receptor in this neoplastic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Finishing the euchromatic sequence of the human genome
International Human Genome Sequencing Consortium (2004) · Nature · doi:10.1038/nature03001 · Cited by 4,971
Handbook of Experimental Immunology.
(1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-68-6-1376_1 · Cited by 2,408
Purified Wnt5a Protein Activates or Inhibits β-Catenin–TCF Signaling Depending on Receptor Context
Mikels, A. J., & Nusse, R. (2006) · PLoS Biology · doi:10.1371/journal.pbio.0040115 · Cited by 1,252
Rosenwald, A., Alizadeh, A. A., Widhopf, G., Simon, R., Davis, R. E., Yu, X., Yang, L., Pickeral, O. K., Rassenti, L. Z., Powell, J., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.11.1639 · Cited by 1,097
Self-citationKlein, U., Tu, Y., Stolovitzky, G. A., Mattioli, M., Cattoretti, G., Husson, H., Freedman, A., Inghirami, G., Cro, L., Baldini, L., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.11.1625 · Cited by 918
The receptor tyrosine kinase Ror2 is involved in non‐canonical Wnt5a/JNK signalling pathway
Oishi, I., Suzuki, H., Onishi, N., Takada, R., Kani, S., Ohkawara, B., Koshida, I., Suzuki, K., Yamada, G., Schwabe, G. C., et al. (2003) · Genes to Cells · doi:10.1046/j.1365-2443.2003.00662.x · Cited by 780
Rassenti, L. Z., Huynh, L., Toy, T. L., Chen, L., Keating, M. J., Gribben, J. G., Neuberg, D. S., Flinn, I. W., Rai, K. R., Byrd, J. C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040857 · Cited by 745
Self-citationHandbook of experimental immunology
Emmrich, F. (1986) · Immunology Today · doi:10.1016/0167-5699(86)90032-0 · Cited by 688
Burger, J. A., Tsukada, N., Burger, M., Zvaifler, N. J., Dell'Aquila, M., & Kipps, T. J. (2000) · Blood · doi:10.1182/blood.v96.8.2655 · Cited by 607
Self-citationRanheim, E. A., & Kipps, T. J. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.4.925 · Cited by 580
Self-citationActivation of the Wnt signaling pathway in chronic lymphocytic leukemia
Lu, D., Zhao, Y., Tawatao, R., Cottam, H. B., Sen, M., Leoni, L. M., Kipps, T. J., Corr, M., & Carson, D. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308648100 · Cited by 420
Self-citationCD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia
Wierda, W. G., Cantwell, M. J., Woods, S. J., Rassenti, L. Z., Prussak, C. E., & Kipps, T. J. (2000) · Blood · doi:10.1182/blood.v96.9.2917 · Cited by 340
Self-citationChronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells
Görgün, G., Holderried, T. A. W., Zahrieh, D., Neuberg, D., & Gribben, J. G. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24176 · Cited by 298
A novel family of cell surface receptors with tyrosine kinase-like domain.
Masiakowski, P., & Carroll, R. D. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35733-8 · Cited by 272
Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1
Pedersen, I. M., Kitada, S., Leoni, L. M., Zapata, J. M., Karras, J. G., Tsukada, N., Kipps, T. J., Choi, Y. S., Bennett, F., & Reed, J. C. (2002) · Blood · doi:10.1182/blood.v100.5.1795.h81702001795_1795_1801 · Cited by 248
Self-citationKato, K., Cantwell, M. J., Sharma, S., & Kipps, T. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1472 · Cited by 232
Self-citationAcquired CD40-ligand deficiency in chronic lymphocytic leukemia
Cantwell, M. J., Hua, T., Pappas, J., & Kipps, T. J. (1997) · Nature Medicine · doi:10.1038/nm0997-984 · Cited by 204
Self-citationA C. elegans Ror receptor tyrosine kinase regulates cell motility and asymmetric cell division
Forrester, W. C., Dell, M., Perens, E., & Garriga, G. (1999) · Nature · doi:10.1038/23722 · Cited by 175
Expression of the receptor tyrosine kinase genes, Ror1 and Ror2, during mouse development
Matsuda, T., Nomi, M., Ikeya, M., Kani, S., Oishi, I., Terashima, T., Takada, S., & Minami, Y. (2001) · Mechanisms of Development · doi:10.1016/s0925-4773(01)00383-5 · Cited by 175
Comparative genomics on Fgf11 orthologs.
Katoh, Y., & Katoh, M. (2005) · Oncology Reports · doi:10.3892/or.14.1.291 · Cited by 169
Lehtonen, A., Ahlfors, H., Veckman, V., Miettinen, M., Lahesmaa, R., & Julkunen, I. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0307194 · Cited by 163
Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells
Ranheim, E. A., Cantwell, M., & Kipps, T. J. (1995) · Blood · doi:10.1182/blood.v85.12.3556.bloodjournal85123556 · Cited by 153
Self-citationLotz, M., Ranheim, E. A., & Kipps, T. J. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.179.3.999 · Cited by 137
Self-citationWilson, C., Goberdhan, D. C. I., & Steller, H. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.15.7109 · Cited by 135
Manual of Molecular and Clinical Laboratory Immunology
(2024) · Wiley eBooks · doi:10.1002/9781683674023 · Cited by 95
Sinisalo, M., Aittoniemi, J., Oivanen, P., Käyhty, H. M., Ölander, R., & Vilpo, J. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02882.x · Cited by 94
Neurite extension in central neurons: a novel role for the receptor tyrosine kinases Ror1 and Ror2
Paganoni, S., & Ferreira, A. (2005) · Journal of Cell Science · doi:10.1242/jcs.01622 · Cited by 86
Functional analysis of the domains of the C. elegans Ror receptor tyrosine kinase CAM-1
Kim, C., & Forrester, W. C. (2003) · Developmental Biology · doi:10.1016/j.ydbio.2003.09.007 · Cited by 75
Influenza virus vaccination and booster in B-cell chronic lymphocytic leukaemia patients
van der Velden, A. M. T., Mulder, A. H. L., Hartkamp, A., Diepersloot, R. J. A., van Velzen‐Blad, H., & Biesma, D. H. (2001) · European Journal of Internal Medicine · doi:10.1016/s0953-6205(01)00149-2 · Cited by 68
Paganoni, S., & Ferreira, A. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10674 · Cited by 41
Cellular immune therapy for chronic lymphocytic leukemia
Kater, A. P., van Oers, M. H. J., & Kipps, T. J. (2007) · Blood · doi:10.1182/blood-2007-01-068932 · Cited by 34
Self-citationHu, D., & Kipps, T. J. (1999) · Cellular Immunology · doi:10.1006/cimm.1999.1513 · Cited by 31
Self-citationBurger, J. A., Mendoza, R. B., & Kipps, T. J. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00382-0 · Cited by 21
Self-citationCD154 Gene Therapy for Human B‐Cell Malignancies
Messmer, D., & Kipps, T. J. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1358.008 · Cited by 18
Self-citationGene therapy and active immune therapy of hematologic malignancies
Wierda, W. G., & Kipps, T. J. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2007.03.006 · Cited by 17
Self-citation
Cited by
WNT signalling pathways as therapeutic targets in cancer
Anastas, J. N., & Moon, R. T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3419 · Cited by 1,911
FGF Receptors: Cancer Biology and Therapeutics: CANCER BIOLOGY AND THERAPEUTICS ON FGF RECEPTORS
Katoh, M., & Nakagama, H. (2014) · Medicinal Research Reviews · doi:10.1002/med.21288 · Cited by 610
The microenvironment in mature B-cell malignancies: a target for new treatment strategies
Burger, J. A., Ghia, P., Rosenwald, A., & Caligaris-Cappio, F. (2009) · Blood · doi:10.1182/blood-2009-06-225326 · Cited by 577
Hudecek, M., Lupo-Stanghellini, M.-T., Kosasih, P. L., Sommermeyer, D., Jensen, M. C., Rader, C., & Riddell, S. R. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0330 · Cited by 544
Kipps, T. J., Stevenson, F. K., Wu, C. J., Croce, C. M., Packham, G., Wierda, W. G., O'Brien, S., Gribben, J., & Rai, K. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.96 · Cited by 517
Self-citation
Metadata
- Authors
- Fukuda, T., Chen, L., Endo, T., Tang, L., Lu, D., Castro, J. E., Widhopf, G. F., Rassenti, L. Z., Cantwell, M. J., Prussak, C. E., Carson, D. A., & Kipps, T. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2008-02-26
- Volume
- 105
- Issue
- 8
- Pages
- 3047-3052
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2145132518
- Cited by
- 312
- References
- 35
- FWCI
- 7.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.